Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754687 · ClinicalTrials.gov registry record · Phase 1
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
A Phase 1 study, sponsored by Premier Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02754687 is a Phase 1 study that has completed, run by Premier Research. The registered enrollment target is 12 participants.
The verdict
NCT02754687, a Phase 1 study, has completed, sponsored by Premier Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.
Interventions
- DRUG Placebo
- DRUG 11βmethyl nortestosterone dodecylcarbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-07-14 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02754687
The ClinicalTrials.gov registry entry for NCT02754687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02754687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02754687 about?
NCT02754687 is a clinical study titled "Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men". The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.
What is the current status of trial NCT02754687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-07-14. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02754687?
The interventions under investigation include: Placebo (DRUG), 11βmethyl nortestosterone dodecylcarbonate (DRUG).
Who is sponsoring clinical trial NCT02754687?
This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.